BayPoint Biosystems Inc

We work with our pharmaceutical, biotechnology and life science partners to develop new drugs based on patient stratification and predicted response. BayPoint’s proteomic technology provides quantitative analysis of flux through signal transduction pathways. Such analysis provides new insights into compounds that modulate these pathways including mechanism of action, on- and off-target activity, system-level pathway flux and responder populations. The technology provides end-to-end drug development support from lead compound prioritization to clinical trials and drug repositioning.